期刊文献+

ERK5对体外血小板活化及在体血栓的影响 被引量:5

Role of ERK5 in platelet activation in vitro and arterial thrombosis in vivo
下载PDF
导出
摘要 目的:探讨细胞外信号调节激酶5(ERK5)对体外血小板聚集及在体血栓的影响及机制。方法:采用Western blot对人血小板中ERK5的表达及其在血小板活化后的磷酸化水平进行检测;采用血小板聚集仪检测ERK5特异性抑制剂XMD8-92对血小板聚集及致密颗粒释放的影响;采用Fe Cl3颈动脉血栓模型检测ERK5对在体血栓的影响;采用Western blot检测XMD8-92对蛋白激酶B(Akt)和人第10号染色体缺失的磷酸酶及张力蛋白同源蛋白(PTEN)磷酸化的影响。结果:人血小板中存在ERK5的稳定表达,其磷酸化水平在血小板活化后显著升高(P<0.05)。XMD8-92可抑制多种血小板激活剂引起的血小板聚集和致密颗粒释放(P<0.05)。Western blot结果表明,XMD8-92可通过下调PTEN Ser370位点磷酸化而增强PTEN的活性,从而抑制Akt的磷酸化,这种抑制效果也通过血小板特异PTEN基因敲除小鼠得到了验证。在体血栓研究表明,XMD8-92经尾静脉给药,可显著延长小鼠第一次颈动脉血栓的形成时间。结论:ERK5可通过影响PTEN的磷酸化调节Akt的活化,进而影响到体外血小板的聚集和在体血栓的形成。 AIM:To investigate the role of extracellular signal-regulated kinase 5(ERK5) in platelet aggregation in vitro and arterial thrombosis in vivo.METHODS:The expression and phosphorylation levels of ERK5 in human platelet were detected by Western blot.The effects of ERK5 selective inhibitor XMD8-92 on platelet aggregation and dense granule secretion were detected by Chrono-Log aggregometer.The effect of ERK5 on in vivo thrombosis was analyzed using an Fe Cl3 artery thrombosis model.The effects of XMD8-92 on protein kinase B(PKB/Akt) and phosphatase and tensin homolog deleted on chromosome ten(PTEN) phosphorylation levels were determined by Western blot.RESULTS:ERK5 was stably expressed in human platelets and its phosphorylation level increased significantly after platelet activation(P 〈0.05).XMD8-92,a selective inhibitor of ERK5,inhibited platelet aggregation and dense granule secretion in response to several platelet stimulators(P 〈 0.05).The results of Western blot showed that XMD8-92 inhibited Akt phosphorylation level by down-regulating PTEN Ser370 phosphorylation and enhancing PTEN activity.The pathway was further confirmed using platelet specific PTEN deficiency mice.The first occlusion time was obviously extended in the mice intravenously given XMD8-92 in the Fe Cl3-induced carotid artery injury model.CONCLUSION:ERK5 plays a role in platelet activation and arterial thrombosis by influencing PTEN and Akt phosphorylation.
出处 《中国病理生理杂志》 CAS CSCD 北大核心 2017年第11期1958-1963,共6页 Chinese Journal of Pathophysiology
基金 国家自然科学基金资助项目(No.81270278) 上海市科委基金资助项目(No.16411965600)
关键词 细胞外信号调节激酶5 血小板 血栓 人第10号染色体缺失的磷酸酶及张力蛋白同源蛋白 Extracellular signal-regulated kinase 5 Platelet Thrombosis Phosphatase and tensin homolog deleted on chromosome ten
  • 相关文献

参考文献5

二级参考文献49

  • 1Bottini N , Firestein GS. Duality of filDroblast-lile synoviocytesin RA : passive responders and imprinted aggressors[J] . Nat Rev R heum atol,2 0 1 3,9 ( 1 ) : 24-33.
  • 2Correia N C, Girio A , Antunes I , et al. The multiplelayers of non-genetic regulation of P T E N tum our suppressoractivity[J] . E ur J C ancer,2 0 1 4,5 0 ( 1 ) : 216-225.
  • 3Pap T , Franz J K , Hummel KM , et al. Activation of synovialfilDroblasts in rheumatoid arthritis : lack of expressionof the tumour suppressor PTEN at sites of invasive growthand destm ction[J] . A rtii/tis R e s,2 0 0 0,2 ( 1 ) : 59-64.
  • 4Lefevre S , Knedla A , Tennie C , et al. Synovial filDroblastsspread rheumatoid a rtii/tis to u n afected jo in ts[J] .Nat M ed,2 0 0 9 , 1 5 (1 2 ) : 1414-1420.
  • 5Scanzello C R , Goldring SR. T h e ro le o fs y n o v itis in o s te o -a rtii/tis patiiogenesis[J] . B one,2 0 1 2 , 51 ( 2 ) : 249-257.
  • 6Pulido R , Baker S J, Barata J T , et al. A unified nomenclatureand amino acid numbering for hum an PTEN [J].Sci Signal,2 0 1 4 , 7 (3 3 2 ) : pe15.
  • 7Song M S, Salmena L , Pandolfi PP. The functions and regulation of tiie PTEN tumour suppressor[J] . Nat Rev MolCell B iol,2 0 1 2 , 1 3 (5 ) : 283-296.
  • 8Hers I , Vincent E E , Tavare JM. Akt signalling in healthand disease[J] . Cell Signal,2 0 1 1,2 3 ( 1 0 ) : 1515-1527.
  • 9Bhutani J , Sheikh A , Niazi AK. Akt inhibitors: m echanismof action and implications for anticancer therapeutics[J] . Infect Agent C ancer,2 0 1 3,8 ( 1 ) : 49.
  • 10Foster J G , Blunt M D , Carter E , et al. Inhibition of PI3Ksignaling spurs new therapeutic opportunities in inflammatory,autoim m une diseases and hematological malignancies[J] . Pharmacol R ev,2 0 1 2 , 6 4 ( 4 ) : 1027-1054.

共引文献159

同被引文献53

引证文献5

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部